A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia

Completed

• Conditions: Achondroplasia

• Registration Number: NCT01603095
• Lead Sponsor: BioMarin Pharmaceutical

Brief Summary

Multicenter, multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in future studies sponsored by BioMarin. No study drug is administered.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04
• Study First Submitted: 2012-05-11
• Study First Submitted QC: 2012-05-18
• Study First Posted: 2012-05-22
• Primary Completion: 2021-02
• Study Completion: 2021-02
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-08
• Last Update Posted: 2021-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 363

Inclusion Criteria

• Parent(s) or guardian(s) willing and able to provide signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, willing and able to provide written assent (as needed) after the nature of the study has been explained and prior to performance of any research-related procedure.
• Aged 0 to <= 17 years, inclusive, at study entry.
• Have ACH, documented by clinical diagnosis
• Are ambulatory and able to stand without assistance (not applicable for infants)
• Are willing and able to perform all study procedures as physically possible.

Exclusion Criteria

• Have hypochondroplasia or short stature condition other than ACH (e.g., trisomy 21, pseudoachondroplasia)

• Have any of the following disorders:

  • Hypothyroidism
  • Insulin-requiring diabetes mellitus
  • Autoimmune inflammatory disease
  • Inflammatory bowel disease
  • Autonomic neuropathy

• Have an unstable clinical condition likely to lead to intervention during the course of the study, including progressive cervical medullary compression

• Growth plates have fused

• Have a history of any of the following:

  • Renal insufficiency
  • Anemia

• Cardiac or vascular disease, including the following:

  • Cardiac dysfunction (abnormal echocardiogram [ECHO] including left ventricle [LV] mass) at Screening Visit
  • Hypertrophic cardiomyopathy
  • Congenital heart disease
  • Cerebrovascular disease, aortic insufficiency
  • Clinically significant atrial or ventricular arrhythmias

• Current treatment with antihypertensive medications angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, drugs known to alter renal function that is expected to continue for the duration of the study

• Have been treated with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the previous 6 months or long-term treatment (> 3 months) at any time

• Have had regular long-term treatment (> 1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable)

• Concomitant medication that prolongs the QT/QTc interval within 14 days or 5 half-lives, whichever is longer, before the Screening visit

• Have used any other investigational product or investigational medical device for the treatment of ACH or short stature

• Have had bone-related surgery or expected to have bone-related surgery during the study period. Subjects with previous limb-lengthening surgery may enroll if surgery occurred at least 18 months prior to the study and healing is complete without sequelae.

• Have any condition that, in the view of the Investigator, places the patient at high risk of poor compliance with the visit schedule or of not completing the study.

• Concurrent disease or condition that, in the view of the Investigator, would interfere with study participation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Collection of consistent growth measurements	Assessed every 3 months for up to 84 months	Patients will be screened and undergo a series of growth measurements on Day 1 and every 3 months thereafter. No study drug is administered.

Trial Locations

Locations (20)

Children's Hospital and Research Center Oakland; 🇺🇸 Oakland, California, United States

Murdoch Children's Research Institute; 🇦🇺 Parkville, Victoria, Australia

The Children's Hospital at Westmead; 🇦🇺 Westmead, Australia

Saitama Children's Medical Center; 🇯🇵 Saitama, Japan

Tokushima University Hospital; 🇯🇵 Tokushima, Japan

Institut Catala de Traumatologica I Medicina de l'Esport; 🇪🇸 Barcelona, Spain

Hospital Universitario Virgen de la Victoria; 🇪🇸 Málaga, Spain

Hospital Sant Joan de Deu Barcelona; 🇪🇸 Barcelona, Spain

Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital; 🇬🇧 London, United Kingdom

Sheffield Children's NHS Foundation Trust; 🇬🇧 Sheffield, United Kingdom

Harbor-UCLA Medical Center; 🇺🇸 Los Angeles, California, United States

Ann and Robert H Lurie Children's Hospital of Chicago; 🇺🇸 Chicago, Illinois, United States

Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

Cincinnati Children's Hospital Medical Center; 🇺🇸 Cincinnati, Ohio, United States

Vanderbilt University; 🇺🇸 Nashville, Tennessee, United States

Osaka University Hospital; 🇯🇵 Osaka, Japan

Medical College of Wisconsin, Children's Hospital; 🇺🇸 Milwaukee, Wisconsin, United States

Nemours/Alfred I. duPont Hospital for Children; 🇺🇸 Wilmington, Delaware, United States

Emory University; 🇺🇸 Decatur, Georgia, United States

Acibadem University School of Medicine; 🇹🇷 Istanbul, Turkey